CAR-T cell therapy has transformed the treatment of B-cell and plasma blood cancers and has rapidly expanded into solid tumors through innovative clinical research. China has become one of the world’s leading destinations for CAR-T cell therapy, with multiple approved products, hundreds of ongoing clinical trials, advanced manufacturing facilities, and internationally recognized cancer centers.
Whether you are considering CAR-T cell therapy after other treatments have stopped working or looking for access to newer therapies not yet available in your country, understanding the treatment journey is the first step.
At Gene Medical, we help international patients access advanced CAR-T cell treatment safely and efficiently by working with experienced physicians, leading hospitals, and dedicated international patient services.
CAR-T Cell Therapy in China at a Glance
China has emerged as one of the world’s leading centers for CAR-T cell therapy research, innovation, and clinical application. Over the past decade, significant investment in biotechnology, cell manufacturing, and cancer research has enabled the country to rapidly advance the development of CAR-T cell therapies.
By June 2026, China’s National Medical Products Administration (NMPA) has approved nine CAR-T cell therapies for the treatment of blood cancers and solid tumors, including CD19 CAR-T cell therapy for B-cell lymphomas and leukemia, BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma and Claudin18.2 CAR-T cell therapy for advanced stomach cancer and gastroesophageal junction cancer.
In addition, China is home to one of the world’s largest CAR-T clinical trial programs. Researchers and hospitals across the country continue to pioneer new CAR-T approaches for T-cell lymphomas and leukemia, glioma, glioblastoma and other solid tumors.
Leading cancer centers in China have treated thousands of patients with CAR-T cell therapy and have accumulated extensive clinical experience in patient selection, treatment, and the management of CAR-T-related side effects. Hospitals like the Institute of Hematology and Blood Diseases Hospital (IHCAMS), Tianjin, University of Hong Kong-Shenzhen Hospital, Gobroad Hospitals and Lu Daopei Hospital have already provided CAR-T cell therapies for over 5,000 patients. Making China a preferred destination for patients seeking advanced CAR-T treatment options that may not yet be available in their home countries.
Understanding CAR-T cell Therapy
CAR-T cell therapy is an advanced form of personalized immunotherapy that uses your own immune cells to help fight cancer. Instead of attacking cancer with drugs alone, CAR-T cell therapy reprograms your T cells—a type of white blood cell—to recognize and destroy cancer cells more effectively. In simple terms, CAR-T cell therapy teaches your immune system to better recognize and attack cancer.
How CAR-T Cell Therapy Works
The treatment process involves several key steps:
- T-cell collection: Your T cells are collected from your blood through a procedure called leukapheresis.
- Cell engineering: In a specialized laboratory, the T cells are genetically modified to produce chimeric antigen receptors (CARs) that recognize specific proteins on cancer cells.
- Cell expansion: The engineered CAR-T cells are multiplied into millions of cells.
- Preparation: Before the infusion, you receive a short course of lymphodepleting chemotherapy to prepare your body for treatment.
- CAR-T infusion: The modified cells are infused back into your bloodstream through an intravenous (IV) line.
- Targeting cancer: Once inside your body, the CAR-T cells multiply, recognize cancer cells carrying the target antigen, and begin destroying them.
Unlike conventional chemotherapy, which affects both cancerous and healthy rapidly dividing cells, CAR-T cell therapy is designed to target cancer cells with greater precision. For some patients with relapsed or refractory blood cancers, it has produced deep, long-lasting responses and, in some cases, complete remission.
Who May Be Eligible for CAR-T Cell Therapy in China?
CAR-T cell therapy is typically considered for patients whose cancer has returned after previous treatment (relapsed) or has not responded adequately to standard therapies (refractory). Whether you are eligible depends on several factors, including your diagnosis, previous treatments, overall health, organ function, and whether your cancer expresses the target antigen for a specific CAR-T therapy.
CAR-T cell therapy in China may be an option for patients with:
Blood Cancers
- Relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Relapsed or refractory Follicular Lymphoma (FL)
- Relapsed or refractory Mantle Cell Lymphoma (MCL)
- Relapsed or refractory Primary Mediastinal B-cell Lymphoma (PMBCL)
- Relapsed or refractory Multiple Myeloma (MM)
- T-cell lymphoma
- T-cell leukemia
- Other high-risk blood cancers after multiple lines of treatment
Solid Tumors
China is also at the forefront of developing CAR-T therapies for selected solid tumors. Eligible patients may have:
- Advanced stomach (gastric) cancer
- Gastroesophageal Junction (GEJ) cancer
- Pancreatic cancer
- Glioma
- Glioblastoma
- Other antigen-positive solid tumors through approved therapies or clinical trials
When CAR-T Therapy May Not Be Suitable
Some patients may need additional treatment or stabilization before CAR-T therapy can be safely administered. CAR-T may not be appropriate for patients with:
- Uncontrolled active infections
- Severe heart, liver, kidney, or lung dysfunction
- Poor overall performance status
- Active or severe neurological disorders
- Uncontrolled central nervous system (CNS) involvement
- Rapidly progressing disease requiring immediate alternative treatment
- Medical conditions where the potential risks outweigh the expected benefits
Every patient is unique. A comprehensive medical review by an experienced CAR-T specialist is essential to determine whether CAR-T cell therapy is the most appropriate treatment option for your individual situation.
Contact us and check eligibility of CAR-T cell therapy→
Why International Patients Choose China for CAR-T Therapy
China has become one of the world’s leading destinations for CAR-T cell therapy, combining cutting-edge research, advanced biotechnology, and extensive clinical experience. With continued investment in cellular immunotherapy, Chinese hospitals and research institutions are helping shape the future of CAR-T treatment for both blood cancers and solid tumors.
China has approved multiple CAR-T products for blood cancers, providing eligible patients with access to established treatments outside of clinical trials.
China is a global pioneer in developing CAR-T therapies for solid tumors, including advanced stomach and gastroesophageal junction (GEJ) cancers, offering new possibilities for patients with limited treatment options.
Leading cancer centers have treated thousands of CAR-T patients, allowing physicians to develop extensive expertise in patient selection, treatment planning, and the management of CAR-T-related side effects.
State-of-the-art GMP-certified manufacturing facilities produce high-quality CAR-T cells under strict quality standards, supporting both commercial therapies and clinical research.
China conducts one of the world’s largest CAR-T clinical trial programs, giving eligible patients access to next-generation therapies, new targets, and combination treatment approaches before they become widely available.
Compared with some countries, patients may be able to begin evaluation and treatment more quickly, reducing delays that can be critical for aggressive cancers.
The overall cost of CAR-T therapy in China is often lower than in many Western countries, while maintaining access to advanced technology, experienced medical teams, and high-quality hospital care.
International patients receive support throughout their medical journey, including medical record review, online consultations, visa assistance, interpreters, travel coordination, accommodation arrangements, and follow-up after returning home.
For some eligible patients, China offers CAR-T therapies and clinical trials that are not yet approved or widely accessible in their home countries, providing additional treatment opportunities when conventional options have been exhausted.
How Long Does CAR-T Cell Therapy Take in China?
Most international patients should plan to stay in China for 4 to 8 weeks, although the exact timeline varies depending on the type of CAR-T therapy, manufacturing time, your medical condition, and recovery after treatment.
The longest stages are typically the CAR-T cell manufacturing process and the monitoring period following the infusion, when your medical team closely watches for side effects and evaluates your response to treatment. The timeline below provides a general overview of what most patients can expect, but your treatment plan will be personalized based on your individual needs.
How Much Does CAR-T Cell Therapy Cost in China?
The cost of CAR-T cell therapy in China varies depending on several factors, including the type of cancer, the CAR-T product used, the treating hospital, the complexity of your condition, and the length of hospitalization. Patients receiving approved commercial CAR-T therapies may also require additional treatments or supportive care, which can affect the overall cost.
For approved CAR-T therapies used to treat blood cancers such as lymphoma, leukemia, and multiple myeloma, treatment typically ranges from USD 70,000 to USD 193,000. Costs may differ for investigational therapies, clinical trials, or CAR-T treatments for solid tumors.
Because every patient’s medical condition and treatment plan are unique, the most accurate way to determine the cost is through a personalized medical review. After evaluating your diagnosis, treatment history, and medical records, our team can provide a tailored treatment plan and cost estimate based on the recommendations of the treating hospital.
Side Effects and Safety
CAR-T cell therapy can cause side effects, ranging from mild symptoms to serious complications. The most closely monitored risks include cytokine release syndrome (CRS), neurological side effects, infections, and low blood counts, particularly during the first days and weeks after treatment.
Patients are closely monitored after CAR-T infusion, with experienced treatment teams prepared to manage these complications if they occur. Follow-up care is also important after discharge to monitor immune recovery, blood counts, and long-term health.
Learn more about CAR-T side effects and safety →
Success Rates and Realistic Outcomes
CAR-T cell therapy has produced remarkable results for some patients, including deep and long-lasting remissions. However, it is not a guaranteed cure, and outcomes can vary considerably from one patient to another.
Results depend on factors such as the type of cancer, the CAR-T product and target used, previous treatments, overall health, and the amount and biology of the disease at the time of treatment.
Some patients achieve complete remission that lasts for years, while others may have only a partial response or may eventually experience disease progression or relapse. In some cases, cancer cells can change or lose the target recognized by the CAR-T cells, allowing the disease to return.
For this reason, published response rates should be viewed as general clinical data rather than a prediction of what will happen to an individual patient. A specialist should review your complete medical history and discuss the potential benefits, limitations, and realistic expectations before treatment.
CAR-T therapy can offer the possibility of deep and durable remission, but every patient’s response is different.
How Do We Help
Cancer is a complex disease that involves multiple appointments, specialized treatments, medications, and ongoing follow-up care — all of which can feel overwhelming, especially for international patients. At CAR T Cell China, we understand these challenges and are committed to supporting you every step of the way. That’s why we’ve developed a dedicated international patient care model, where a personal care coordinator or team is assigned to help manage the entire treatment journey — from visa support and travel logistics to hospital navigation and medical appointments.
Your care manager at CAR T Cell China is a highly trained nurse or patient liaison with deep expertise in cancer care and CAR-T therapy. They serve as your primary point of contact, coordinating everything from consultations with top specialists to treatment scheduling, medication support, and ongoing communication with your medical team.
As a trusted bridge between you and your care providers, your care manager ensures that no detail is overlooked — allowing you to focus fully on your recovery, while we handle the rest.
Every Detail Matters
Finding the right cancer treatment center and care team is one of the most important decisions you’ll make — especially when seeking care abroad. At CAR T Cell China, we understand the weight of that decision and the stress it can bring. That’s why we are committed to making your experience as convenient, affordable, and worry-free as possible. From personalized care coordination to access to cutting-edge CAR-T therapy, we work every day to ensure that international patients receive not only world-class treatment, but also the dedicated support they need throughout their journey. Here are just a few of the key advantages of choosing CAR T Cell China as your care destination.
Get a second opinion
Being diagnosed with a serious illness like cancer can turn your world upside down — and the decisions you make next are crucial to achieving the best possible outcome. At CAR T Cell China, we believe that you deserve to fully understand all of your options so you can confidently participate in decisions about your care.
Even if you’ve already started treatment elsewhere, you can still seek a second opinion from our leading CAR-T specialists.
Our expert team will carefully review your diagnosis, assess your treatment history, and provide clear insights into the most advanced CAR-T therapies and clinical options available in China. We take time to listen to your concerns, answer your questions, and help you make informed choices. Our experience comes from treating blood cancers at every stage, every day. Contact us today to schedule your second opinion consultation — and take the next step with confidence.